Multi-Cancer Blood Tests Test FDA's Screening Standards

At least five multi-cancer early detection blood tests are currently under active federal review or pending clearance, as biotech companies backed by hundreds of millions in venture capital push regulators to define what counts as adequate proof that screening healthy people saves lives. The FDA has not yet approved any multi-cancer early detection test for general screening use, a gap that sits at the center of a mounting scientific and commercial dispute over how early detection should be validated before it reaches patients.

What Multi-Cancer Early Detection Tests Actually Do

Multi-cancer early detection tests — commonly called MCED tests — work by analyzing cell-free DNA, proteins, or other molecular signals circulating in a blood sample to identify whether cancer-associated changes are present, and in some cases to predict which organ the cancer may have originated from. The appeal is straightforward: a single blood draw that might catch lung, pancreatic, colon, or ovarian cancer before symptoms appear.

The science behind circulating tumor DNA has been studied for more than a decade, but translating laboratory sensitivity into real-world population screening is a substantially more complex challenge, according to oncologists and epidemiologists who have reviewed the available trial data. Detecting a signal in a blood sample is not the same as proving that acting on that signal prevents cancer deaths — a distinction the FDA has placed at the center of its review framework. (Source: FDA, NIH National Cancer Institute)

How the Tests Identify a Signal

Most MCED platforms use machine learning algorithms trained on blood samples from confirmed cancer patients and cancer-free controls. The algorithm learns patterns associated with cancer-derived DNA methylation or protein expression. When a new sample is analyzed, the model assigns a probability score. If that score crosses a defined threshold, the test reports a positive result — sometimes with a tissue-of-origin prediction, sometimes without.

The challenge regulators and independent scientists emphasize is that sensitivity and specificity figures from case-control studies — where researchers already know who has cancer — tend to look more favorable than performance in a prospective screening population where cancer prevalence is far lower. In a population where the true cancer rate might be less than one percent, even a test with 99 percent specificity will generate a meaningful proportion of false positives.

The FDA's Regulatory Framework Under Pressure

The FDA classifies MCED tests as high-risk medical devices requiring premarket approval, the most rigorous pathway the agency applies. Premarket approval demands that manufacturers demonstrate reasonable assurance of safety and effectiveness — a standard the agency has clarified means prospective clinical evidence showing the test produces benefit in a screened population, not simply that it detects cancer at earlier stages. (Source: FDA)

That stance has created tension with several companies that argue the agency's evidentiary bar is impractically high for a technology that could prevent deaths from cancers that currently have no recommended screening test. Pancreatic cancer, for example, has a five-year survival rate of roughly 12 percent largely because most cases are diagnosed at an advanced stage, according to data from the American Cancer Society.

The Randomized Trial Question

At the heart of the regulatory debate is whether MCED makers must demonstrate mortality reduction in a randomized controlled trial before broad clearance — a process that can take ten years or more — or whether surrogate endpoints such as stage shift can serve as sufficient evidence. Stage shift refers to a test detecting cancer at an earlier, more treatable stage compared to standard care.

The FDA has signaled that it will consider accelerated approval pathways for some tests using stage shift as a surrogate, but has stopped short of committing to a universal standard, leaving companies and clinical trial designers working with significant uncertainty. The agency convened an advisory panel session on the topic recently, drawing formal comments from oncology professional societies, patient advocacy groups, and academic researchers. (Source: FDA, JAMA Oncology)

Who Is Behind the Technology and What They Have Filed

Grail, a company spun out of Illumina and subsequently acquired and then divested through a lengthy antitrust process, has filed for FDA premarket approval of its Galleri test — currently the highest-profile submission in the MCED category. The company has not received approval for screening use and continues to market the test as a laboratory-developed test available by prescription, a category that until recently faced lighter federal oversight.

Exact Sciences, Guardant Health, and several smaller players have also indicated development programs targeting multi-cancer detection, with varying pipeline stages. The commercial pressure to reach market is significant: analysts have projected the MCED market could exceed tens of billions of dollars annually if one or more tests receive regulatory clearance and insurance coverage. (Source: Reuters Health, company filings via SEC)

The convergence of large commercial stakes and unresolved science is precisely the scenario that has historically tested the FDA's ability to hold a consistent evidentiary line. For context on how federal agencies navigate similar technology-meets-evidence tensions, the regulatory dynamics around novel cancer detection methods challenging established diagnostic standards illustrate the broader pattern the agency is managing across oncology screening.

Laboratory-Developed Test Loophole

For years, clinical laboratories have been able to offer tests developed and performed in-house under a framework that required less rigorous federal premarket review than device clearance. The FDA recently finalized a rule that significantly narrows this pathway, requiring most laboratory-developed tests to go through standard device review. That change directly affects MCED tests currently offered without formal FDA approval and has set a compliance timeline that the industry is actively contesting. (Source: FDA, AP)

Coverage, Cost, and the Insurance Gap

Even if the FDA were to approve an MCED test tomorrow, payment would not follow automatically. The Centers for Medicare and Medicaid Services makes independent coverage determinations, and CMS has historically required its own evidence review before agreeing to reimburse a screening test for Medicare beneficiaries — the demographic most likely to benefit from earlier cancer detection.

The Medicare Coverage of Innovative Technology pathway exists specifically for breakthrough-designated devices, but its application to cancer screening remains contested, partly because the coverage-with-evidence-development model — which provides payment while additional real-world data are collected — has shown mixed results in producing the follow-on evidence it is designed to generate. The dynamics around Medicare's ability to move at the pace of innovative medical technology reflect a structural challenge that extends well beyond any single disease area.

Out-of-pocket costs for currently available MCED tests range from several hundred to over one thousand dollars, placing them effectively beyond reach for a large share of the uninsured and underinsured population — groups that also carry disproportionately high cancer mortality burdens, according to CDC surveillance data. (Source: CDC, CMS)

What Clinicians and Independent Scientists Are Saying

Several professional bodies, including the American Society of Clinical Oncology and the American Cancer Society, have issued statements acknowledging the potential of MCED technology while explicitly declining to recommend its use in routine clinical practice pending further evidence. Their primary concerns center on the downstream consequences of a positive result that is not confirmed by imaging or biopsy — repeated imaging exposures, invasive procedures, patient anxiety, and costs that could displace spending on established care. (Source: NEJM Evidence, American Cancer Society)

Independent biostatisticians have also raised methodological concerns about how some published MCED studies selected their control populations and defined their performance endpoints, arguing that headline sensitivity figures do not translate directly to expected performance in an asymptomatic screening population. The NIH's National Cancer Institute is currently funding several independent evaluation efforts designed to provide data outside of company-sponsored trials. (Source: NIH National Cancer Institute)

The question of how diagnostic technology shapes patient expectations is not unique to cancer screening. Similar tensions around premature clinical adoption have emerged in areas such as wearable health sensors detecting physiological changes before conventional tests confirm them — cases where the technology outpaces the validated clinical response framework.

The False Positive Burden

Oncologists and primary care physicians who have written about early MCED adoption in peer-reviewed literature describe a practical challenge: when a test returns a positive result with a tissue-of-origin prediction, clinicians feel compelled to initiate workups, but the diagnostic pathway for a signal without a known tumor location is not standardized. PET-CT imaging, endoscopy, biopsy — the cascade can be both physically and financially burdensome, and in false-positive cases, it delivers no benefit while carrying real risks. (Source: NEJM, JAMA)

The Policy Path Forward

Congress has shown interest in expediting access to MCED tests through proposed legislation that would direct CMS to cover a federally approved MCED test for Medicare beneficiaries. Proponents argue the potential to shift cancer diagnoses from late to early stage justifies acting ahead of mortality outcome data. Critics, including some health economists and bioethicists, counter that mandating coverage before mortality benefit is established could cause net harm at the population level while consuming substantial public resources. (Source: AP, Congressional Research Service)

The FDA, for its part, has said it intends to issue formal guidance specific to MCED tests to clarify the evidentiary requirements it will apply — a document the industry has been awaiting. Until that guidance is published and a first approval is granted or denied, the regulatory and commercial standoff will continue to shape how physicians counsel patients asking about blood-based cancer screening. The broader context of how federal health agencies build and sometimes strain public confidence through high-stakes decisions is visible in parallel debates, including discussions around federal health agency credibility during moments of regulatory pressure.

• Patients interested in MCED tests should discuss their personal cancer risk history with a physician before pursuing testing
• No MCED test currently has FDA approval for routine screening in asymptomatic adults
• A positive result from a currently available MCED test requires diagnostic follow-up and should not be treated as a cancer diagnosis
• Insurance coverage is not standard — patients should verify costs in advance and ask about financial assistance programs
• Established cancer screening tests — mammography, colonoscopy, low-dose CT for high-risk smokers, cervical cancer screening — remain the standard of care recommended by the US Preventive Services Task Force
• Patients with a family history of cancers that lack standard screening tests may wish to discuss genetic counseling as a complement to any emerging detection technologies

The race to bring multi-cancer blood tests into mainstream American medicine is unfolding on two tracks simultaneously: a scientific track in which researchers are still assembling the evidence base, and a commercial and regulatory track in which billions of dollars and the FDA's institutional authority over diagnostic standards are both at stake. The resolution — whatever form it takes — will set a precedent for how the United States evaluates an entire generation of molecular screening technologies now moving through development pipelines.